#Twist bioscience full#
#Twist bioscience license#

An export license will be required for international customers. Customers purchasing synthetic controls are subject to Twist’s leading biosecurity and customer screening protocols and applicable laws and regulations. Each control is made up of 1.8kb of overlapping fragments that tile the genome.

#Twist bioscience full#

The monkeypox synthetic DNA controls are designed based on specific monkeypox clades, cover over 80% of the full viral genome and are sequence-verified using NGS and ddPCR. “As new and existing pathogens emerge as public health concerns, we will continue to rapidly develop tools to enable cutting edge research that improve global health outcomes.”

Leproust, Ph.D., CEO and co-founder of Twist Bioscience. They also complement our growing suite of NGS applications for viral diseases, including the Twist Pan-Viral Panel, which was used by researchers to characterize the monkeypox pathogen in a previous outbreak and highlighted in The Lancet 2,” said Emily M. 'The monkeypox controls are the most recent addition to our expanding portfolio of synthetic controls and reference standards that empower our customers to develop research and diagnostic tests to improve global health. The Twist synthetic DNA controls include both known clades of the monkeypox virus, currently named the Congo Basin (Central African) clade and the West African clade, the latter of which has been identified as the predominant clade in the current multi-country outbreak. Positive controls provide quality control measures for the development, verification, and ongoing validation of both next-generation sequencing (NGS) and polymerase chain reaction (PCR) assays. In that settlement, neither Agilent nor Twist admitted any liability or wrongdoing.SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today launched two human monkeypox virus synthetic DNA controls 1. Agilent, a 20-year old synthetic DNA manufacturer, alleged that Leproust misappropriated trade secrets and was in breach of contract when she left Agilent to start Twist with co-founders Bill Banyai and Bill Peck. Smith had previously helped lead the expansion of a government affairs program at Gilead.Īnd in February, Twist and Leproust spent $22.5 million to settle one of the biggest issues hanging over the company - a four-year legal battle over Leproust’s departure from Agilent. In July, the company tapped Erin Smith to be its senior vice president of government affairs and public policy, a newly-created position. Twist will create a TCR library - a self-proclaimed “library of libraries” - to aid Neogene’s search for engineered TCRs against targets in cancer, and Twist will also use the library to discover antibodies for future Neogene CAR-T candidates. Most recently, the company in October announced a collaboration with Neogene to study CAR-T and TCR therapies for cancer patients. However, Twist said it expected the plant to bring some 400 jobs to the area by the time it’s up and running.īeyond its “factory of the future,” Twist has had a busy 2020. The capital outlay associated with the facility, located more specifically in Wilsonville, was kept under wraps. “The (factory) allows us to support the increasing needs of our customers as they scale globally and plan for aggressive growth into synthetic biology and biopharma market segments we cannot serve today.” “We are expanding our customer base and ramping production of our products at an exceptional rate,” she said.